The $45 Billion Lesson Indian Pharma Isn't Learning

When Narayana Murthy forced out Vishal Sikka, Infosys’ CEO, he sealed the company’s fate. Sikka wanted to invest $1B in OpenAI. That stake would be worth $45B today. While the money is very attractive, more importantly, it would set India’s leading IT company to redefine that industry and probably save millions of jobs while inspiring hundreds of start ups to build better. The lesson is about what happens when founders confuse the model that built their industry with the model that will define its future.Indian pharma is running the same risk. We built a world-class generics industry on manufacturing arbitrage and regulatory navigation. Brilliant execution but the ceiling is visible - USFDA pressure, China competition, DPCO constraints, generic price erosion in the US.The Sikkas of Indian pharma exist - in biologics, in novel discovery, in platform chemistry - but the institutional gravity (and inertia) of a promoter-controlled, generics-benchmarked industry is immense. The question every pharma CXO and capital allocator should be asking is “are we scaling yesterday’s model, or building tomorrow’s?” Listen in. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com